Ethambutol

Introduction Overview

Generic Name

ethambutol

Brand Name

Myambutol

Dosage Form

oral tablet (100 mg; 400 mg)

Drug Class

Miscellaneous antituberculosis agents

Pharmacokinetics

Ethambutol displays distinct pharmacokinetic properties essential for its use in tuberculosis treatment.

Absorption: Ethambutol is well absorbed orally, with bioavailability reported in the range of 80%. Peak plasma concentrations are generally achieved within 2 to 4 hours post-administration. The presence of food may slightly delay absorption but does not significantly affect overall bioavailability, allowing administration with or without food. However, co-administration with aluminum-containing antacids decreases absorption significantly, hence such antacids should be avoided within four hours of dosing due to impaired ethambutol uptake.

Distribution: Following absorption, ethambutol distributes widely throughout body tissues and fluids. It penetrates well into pulmonary tissues, including alveolar macrophages where Mycobacterium tuberculosis resides, enhancing its therapeutic effect. Ethambutol crosses the blood-brain barrier variably, achieving cerebrospinal fluid concentrations approximately 10-20% of simultaneous plasma levels, which may be clinically relevant in central nervous system tuberculosis. Protein binding is low, estimated at 20-30%, facilitating distribution to tissues.

Metabolism: Ethambutol undergoes minimal hepatic metabolism; the majority of the administered dose exists as unchanged drug in plasma and urine. Its limited metabolism reduces concerns of drug-drug interactions mediated via hepatic enzyme systems but demands dose adjustments in renal impairment due to elimination pathways.

Elimination: Renal excretion is the primary elimination route for ethambutol, with approximately 80% to 90% of unchanged drug eliminated via the kidneys within 24 hours. The elimination half-life averages between 3 to 4 hours in patients with normal renal function but can be prolonged significantly in renal insufficiency, necessitating dosage adjustment. Dialysis can remove ethambutol to some extent. Monitoring renal function is crucial to prevent accumulation and potential toxicity, especially optic neuritis. Clinical studies underscore dose modification importance in patients with moderate to severe renal impairment to maintain safety and efficacy.

Dosage Forms

Available Dosage Forms:
Ethambutol is commercially available as oral tablets in two strengths: 100 mg and 400 mg. These tablets facilitate flexible dosing regimens, allowing precise dosing adjustments according to patient weight and clinical needs.

Dosages for Adults and Adolescents:
Typical adult dosing for tuberculosis treatment is weight-based, generally 15 mg/kg orally once daily, with a minimum dose of 25 mg/kg/day and maximum doses not exceeding 25 mg/kg/day to balance efficacy and toxicity risk. For initial tuberculosis therapy, ethambutol is often combined with other antituberculous agents. The treatment duration and dosage adjustments may vary depending on the patient's weight, severity of disease, history of previous antituberculous treatment, and presence of drug resistance. Adolescents aged 13 and above are dosed similarly to adults; however, ethambutol use is contraindicated for children under 13 years due to insufficient safety and efficacy data and heightened risk of optic toxicity.

Specific Patient Populations:
Dose adjustments are essential for patients with renal impairment because ethambutol is primarily renally excreted and can accumulate, increasing the risk of optic neuritis. Dosing intervals may be extended or doses reduced based on creatinine clearance. In hepatic impairment, no significant dosage alteration is typically necessary due to minimal hepatic metabolism. Ethambutol is classified as pregnancy category C; its use during pregnancy is reserved for cases where benefits outweigh potential risks, and close monitoring is advised. It is excreted in breast milk; nursing mothers should consult healthcare providers about breastfeeding during therapy. Elderly patients require careful monitoring but generally receive standard dosing unless renal compromise is evident.

Mechanism Of Action

Ethambutol is a bacteriostatic antitubercular agent that specifically targets Mycobacterium species by disrupting cell wall synthesis. Its primary molecular mechanism involves inhibition of arabinosyl transferases, enzymes critical for the polymerization of arabinogalactan, an essential component of the mycobacterial cell wall. By inhibiting these enzymes, ethambutol impairs the incorporation of arabinose residues into the cell wall, leading to increased cell wall permeability and disruption of cell wall integrity.

At the cellular level, this disruption hinders cell wall biosynthesis, which compromises the bacterial cell’s structural stability and function, ultimately stunting replication and survival. Ethambutol's selective inhibition is effective against Mycobacterium tuberculosis and certain atypical mycobacteria. The drug’s action is slower compared to bactericidal agents because it does not kill the bacteria directly but inhibits their growth.

Biochemically, ethambutol binds to the EmbB protein, part of the arabinosyl transferase complex, interfering with D-arabinofuranosyl transferase activity. This biochemical interaction is crucial for the addition of arabinogalactan in the cell envelope. This interference weakens the protective mycobacterial cell wall, making the organism more susceptible to host defenses and the action of other antituberculous drugs.

Clinically, ethambutol is employed as part of multidrug regimens to prevent emergence of resistant tuberculosis strains. Its mechanism complements other antituberculous drugs such as isoniazid and rifampin, which target different bacterial pathways. Comparative studies show ethambutol’s critical role in combination therapy, particularly for managing drug-resistant TB and as a first-line agent during intensive treatment phases. Research evidence supports its efficacy in reducing bacillary load and limiting resistance development when used appropriately in combination therapy.

Pharmacological Actions

Bacteriostatic activity against Mycobacterium tuberculosis and atypical mycobacteria by inhibiting cell wall biosynthesis.
Selective inhibition of arabinosyl transferases involved in arabinogalactan polymerization.
Disruption of mycobacterial cell wall formation leading to increased permeability.
Facilitates efficacy of other antituberculosis agents by weakening mycobacterial defenses.
Prevention of the emergence of multi-drug resistant tuberculosis strains when used in combination therapy.
Minimal direct hepatic metabolism, reducing the potential for hepatic drug interactions.
Concentration-dependent activity with improved effects at higher plasma concentrations within therapeutic range.
Effective penetration into pulmonary and other tissues affected by tuberculosis.
Low protein binding enabling widespread tissue distribution.
Primarily renally excreted, allowing for predictable elimination kinetics.
No significant effect on cytochrome P450 enzymes, minimizing many drug interaction risks.
Limited impact on normal bacterial flora compared to broad-spectrum antibiotics.
Bacteriostatic rather than bactericidal, requiring combination with other agents for complete mycobacterial clearance.
Does not exhibit cross-resistance with isoniazid or rifampin, facilitating multi-drug regimens.

Therapeutic Or Clinical Uses

First-line agent as part of multidrug therapy for active pulmonary tuberculosis.
Treatment of tuberculosis infections caused by Mycobacterium tuberculosis complex.
Management of infections due to atypical mycobacteria, including Mycobacterium avium-intracellulare complex.
Used as a component of initial intensive therapy to prevent emergence of drug resistance.
Part of maintenance therapy regimens in certain tuberculosis treatment protocols.
Adjunctive therapy in multidrug-resistant tuberculosis cases where sensitivity permits.
Prophylactic use in high-risk patients possibly exposed to drug-resistant mycobacterial strains in combination with other agents.
Treatment of tuberculous meningitis and disseminated tuberculosis infections in combination with other anti-TB agents, despite limited CNS penetration.
Used in patients intolerant to standard first-line agents when appropriate alternatives are necessary.
Therapeutic option in tuberculosis patients with coexisting liver disease due to minimal hepatic metabolism.
Treatment of TB infections resistant to isoniazid or rifampin when susceptibility supports inclusion.
Part of multidrug regimens recommended by WHO and CDC for tuberculosis management.
Utilized in combination therapy to reduce bacterial burden and improve treatment duration and outcomes.
Off-label use in certain refractory mycobacterial infections under specialist supervision.
Important role in global tuberculosis control programs due to potency and safety profile.

Side Or Adverse Effects

Optic neuritis resulting in reduced visual acuity, color blindness (especially red-green color perception), and visual field defects; may be irreversible if undetected.
Blurred vision, loss of vision in one or both eyes, increased photosensitivity, and eye pain.
Hypersensitivity reactions including rash, itching, and erythema.
Gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and loss of appetite.
Headache and dizziness reported in some patients.
Joint pain or arthralgia during therapy.
Peripheral neuropathy marked by numbness or tingling in extremities.
Rare severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hepatotoxicity manifested as elevated liver enzymes, jaundice, and dark urine in rare cases.
Fever, swollen glands, and painful mouth or skin sores potentially indicating hypersensitivity.
Easy bruising or bleeding tendencies, such as nosebleeds or bleeding gums.
Confusion, hallucinations, or other neuropsychiatric symptoms rarely reported.
Potential renal toxicity in predisposing conditions due to drug accumulation.
Increased risk of adverse effects in patients with pre-existing ocular disorders.
Allergic reactions including anaphylaxis, though uncommon.

Precautions

Baseline and regular ophthalmological evaluations are mandatory to monitor for signs of optic neuritis.
Caution in patients with pre-existing eye disorders such as optic neuritis, diabetic retinopathy, cataracts, uveitis, or iritis.
Dose adjustments recommended in renal impairment to prevent drug accumulation and toxicity.
Monitor liver function periodically despite minimal hepatic metabolism, particularly in patients with liver disease.
Avoid in children under 13 years due to lack of established safety and increased risk of ocular toxicity.
Use cautiously during pregnancy and lactation; only if potential benefits justify risks to fetus or infant.
Patients should immediately report any visual changes including loss of vision, color perception defects, or eye pain.
Ethambutol can be taken with or without food; however, avoid concomitant use with aluminum-containing antacids within 4 hours.
Weight monitoring advised to adjust dosage appropriately during treatment.
Contraindicated in patients unable to reliably report vision changes (e.g., young children, debilitated individuals).
Patients should be educated on adherence to full course to prevent resistance development.
Regular hematologic and renal function testing recommended during prolonged therapy.
Avoid sudden dose changes or premature discontinuation without consulting healthcare provider.
Potential cross-sensitivity with other antimycobacterial agents should be assessed.
Ensure no concomitant use of contraindicated drugs which could exacerbate toxicity.

Warnings

Ethambutol can cause serious and potentially irreversible vision problems, including optic neuritis leading to permanent vision loss.
Prompt discontinuation required at the first sign of visual disturbance to prevent irreversible damage.
Not suitable for patients with pre-existing optic neuritis or severe eye disease.
Ethambutol may interact with aluminum-containing antacids reducing absorption; avoid concomitant administration within 4 hours.
Use with caution in renal impairment as drug accumulation increases risk of adverse effects.
Monitor for signs of hypersensitivity reactions including severe skin eruptions and systemic symptoms.
Pregnancy category C: only use if clearly needed and potential benefit justifies risk to fetus.
Patients should avoid self-adjusting dosage or discontinuing therapy abruptly to prevent treatment failure and resistance.
Potential for hepatotoxicity warrants monitoring despite low hepatic metabolism.
Increased risk of neuropathy in patients with pre-existing peripheral neuropathy or those taking other neurotoxic agents.
Use in pediatric patients under 13 years is contraindicated due to higher risk of optic toxicity.
Patients with hepatic or renal impairment require close medical supervision due to altered pharmacokinetics.
Ethambutol therapy requires careful coordination with other antitubercular drugs to optimize efficacy and minimize toxicity.
Vision testing including color discrimination and visual acuity assessments should be conducted regularly.
Patients must be cautioned about the risk of allergic reactions and the importance of seeking immediate care if symptoms develop.

Contraindication

Known hypersensitivity or allergic reactions to ethambutol or any ingredient of the formulation.
Pre-existing optic neuritis or other significant optic nerve disorders.
Patients unable to reliably report visual symptoms (e.g., young children under 13, debilitated or cognitively impaired patients).
Severe renal impairment without appropriate dose adjustment.
Concomitant use with aluminum-containing antacids without adequate time separation.
Use in pediatric population under 13 years is contraindicated due to lack of safety data and risk profile.
Known severe hypersensitivity reactions to structurally related compounds may preclude use.
Patients with pre-existing retinal disease or severe ocular toxicity history.
Situations where close ophthalmologic monitoring is not feasible.
Concurrent use with drugs causing optic neuropathy must be avoided or monitored with caution.
Hypersensitivity to any antitubercular drug with cross-reactivity concerns.
Severe hepatic impairment warranting avoidance based on clinical judgment.
Active severe allergic skin reactions preclude introduction of ethambutol until resolved.
Incompatibility with certain drugs reducing absorption or increasing toxicity risks.
Any contraindication to combination antitubercular regimens involving ethambutol.

Drug Interactions

Aluminum-containing antacids (e.g., Alternagel, Maalox, Mylanta): reduce ethambutol absorption if taken within 4 hours.
Other antituberculosis agents: generally used in combination; interactions require monitoring for additive toxicity.
Drugs causing optic neuritis or neurotoxicity (e.g., isoniazid, linezolid): co-administration increases risk of optic and peripheral neuropathy.
Renally excreted drugs: competition for excretion may alter plasma levels; dose adjustments may be necessary.
Corticosteroids: may mask signs of hypersensitivity but generally no direct interaction reported.
Rifampin: may induce hepatic enzymes but minimal direct impact on ethambutol pharmacokinetics.
Vitamin B6 (pyridoxine): supplementation recommended to mitigate neuropathy risk when combined with isoniazid but does not interact directly with ethambutol.
Other nephrotoxic agents: increased risk of renal impairment requiring careful monitoring.
Cholestyramine and other bile acid sequestrants: potential reduction in absorption if co-administered, no robust data.
Oral contraceptives: unlikely significant interaction but clinical vigilance advised.
Immunosuppressive therapies: no direct interactions but overall immune status can affect therapy outcomes.
Herbal supplements: lack of data; caution advised particularly with products affecting renal or hepatic function.
Other antibiotics like fluoroquinolones: no significant interaction but combined toxicities must be considered.
Methotrexate: possible additive neurotoxicity or bone marrow suppression reported anecdotally.
Antiretrovirals in HIV-TB coinfection: no major direct interactions but complex regimens increase monitoring complexity.

Preparations Of The Drug

Oral tablets available in 100 mg strength for flexible dosing and titration purposes.
Oral tablets available in 400 mg strength to facilitate higher dose regimens in adults.
Tablets are film-coated to enhance stability and ease of swallowing.
Packaged in bottles matching recommended treatment courses to reduce double handling risks.
Commercial preparations designed for daily oral administration.
Available as prescription-only medicines under brand name Myambutol and generics.
Stored at controlled room temperature away from moisture and excessive heat to maintain potency.
Formulations compatible with combination tuberculosis therapy regimens.
No injectable formulations commercially available for ethambutol as use is primarily oral.
Manufactured under Good Manufacturing Practices ensuring consistent quality and efficacy.
Tablets suitable for administration with or without food, improving patient compliance.
Available with detailed package inserts containing safety and dosing instructions.
Formulations free of common allergens facilitating use in sensitive patients.
Single-agent formulations enabling dose adjustment without interference from other components.
Prepared with standard excipients to optimize bioavailability and minimize adverse effects.